Search results
Results from the WOW.Com Content Network
Levetiracetam, sold under the brand name Keppra among others, is a novel antiepileptic drug [7] used to treat epilepsy. [8] It is used for partial-onset , myoclonic , or tonic–clonic seizures, [ 7 ] and is taken either by mouth as an immediate or extended release formulation or by injection into a vein .
Seletracetam (UCB 44212) is a pyrrolidone-derived [2] drug of the racetam family that is structurally related to levetiracetam (trade name Keppra). [2] [3] It was under development by UCB Pharmaceuticals as a more potent and effective anticonvulsant drug to replace levetiracetam but its development has been halted.
Lipinski's rule of five, also known as Pfizer's rule of five or simply the rule of five (RO5), is a rule of thumb to evaluate druglikeness or determine if a chemical compound with a certain pharmacological or biological activity has chemical properties and physical properties that would likely make it an orally active drug in humans.
The action of drugs on the human body (or any other organism's body) is called pharmacodynamics, and the body's response to drugs is called pharmacokinetics. The drugs that enter an individual tend to stimulate certain receptors , ion channels , act on enzymes or transport proteins .
Clinical pharmacology is "that discipline that teaches, does research, frames policy, gives information and advice about the actions and proper uses of medicines in humans and implements that knowledge in clinical practice". [1] [2] Clinical pharmacology is inherently a translational discipline underpinned by the basic science of pharmacology ...
A drug class is a group of medications and other compounds that share similar chemical structures, act through the same mechanism of action (i.e., binding to the same biological target), have similar modes of action, and/or are used to treat similar diseases. [1] [2] The FDA has long worked to
Agonist vs. antagonist. In pharmacology the term agonist-antagonist or mixed agonist/antagonist is used to refer to a drug which under some conditions behaves as an agonist (a substance that fully activates the receptor that it binds to) while under other conditions, behaves as an antagonist (a substance that binds to a receptor but does not activate and can block the activity of other agonists).
The journal was established in 1966 as the Australian Journal of Hospital Pharmacy with Fred J. Boyd and Charles B Macgibbon as the founding editors-in-chief. [2] The journal obtained its current title in 2002. Since 2014, the journal is published by John Wiley & Sons on behalf of the SHPA. [3]